The product was used in Ukraine Clinical Trial and has proven excellent results for hospitalized covid-19 patients.

CLINICAL STUDY MAF capsules efficacy in post-COVID syndrome treatment is started in KAZAKHSTAN

CLINICAL STUDY MAF capsules efficacy in post-COVID syndrome treatment is started in KAZAKHSTAN

MedInc Ltd in Kazakhstan on the base of National Research Cardiac Surgery Center has started the implementation of prospective randomized open-label clinical trial: “Evaluation of immune modulator MAF capsules efficacy in a therapy of patients with post-COVID syndrome”. The study sponsored by the developer and manufacturer of the study product Saisei Pharma Co. Ltd, Japan.

The goal of the study is the evaluation of the safety and efficiency of a MAF capsules dietary supplement with anti-inflammatory immune response modulating function in combined treatment of the post-COVID syndrome. |

The trial started in February 2021 and targeted 200 patients with post-COVID syndrome, which will be randomized 1:1 in two groups:
Group 1: SOC (standard of care) + dietary supplement MAF capsules administration for 30 days.
Group 2: SOC

The study primary endpoints aim to evaluate the improvement within 30 days period after MAF capsules administration, where the clinical efficacy refers to an improvement of life quality according to Chalder Fatigue Scale and the “Postcovid syndrome” consequences and symptoms severity evaluation according to ISARIC questionnaire.

The study secondary endpoints included the evaluation of changes according to the Karnofsky Performance Scale and Numerical Rating Scale, and evaluation of the MAF capsules side effects.

The exploratory endpoints include effects on:
1. Lymphocyte count, T cells and its subpopulation count, and B cells count
2. The plasma level of IgG against SARS-CoV-2

6-Jan-2021

Clinical trial using MAF for hospitalized COVID-19 patients in Ukraine

In June 2020 we applied to the COVID-19 Scientific Technical Triage of the US FDA for the evaluation of the rationale to study the efficacy of MAF Capsules in COVID-19 treatment. The US FDA in PreIND 151946 meeting response recommended a small proof of concept (POC) study as the initial step prior to the large-scale trial be run. The US FDA indicated recommendations including the major study endpoints addressing the investigation of MAF Capsules efficacy as a potential new drug was implemented in the proposed study design. The recommended efficacy endpoints were also implemented in the open-label randomized clinical trial that started in Ukraine in November 2020 to assess the efficacy and safety of dietary supplements MAF Capsules, 148 mg and M Capsules, 148 mg in addition to standard of care (SOC) compared with SOC in the treatment of hospitalized non-critical COVID-19 patients.

Summary of preliminary results of clinical study

The ongoing interim study results showed a decrease in all-cause mortality and necessity of oxygen supply, as the mortality was 4/15 in the control group, vs 0/16 and 1/17 of currently enrolled patients in the MAF Capsules and M Capsules groups respectively. The mean duration of supplemental oxygen was 8.5 days in the control group, vs 4.1 and 5.1 days in the MAF Capsules and M Capsules groups respectively. MAF Capsules, which is under investigational new drug process, is a dietary supplement that targets guts mucosal immunity to modulate macrophages functionality, limiting epithelial damage, and controlling inflammation response during COVID-19.

Clinical trial groups:

  • Control group
  • MAF Capsules (colostrum MAF) group
  • M Capsules (whey MAF) group

Patients randomized 1:1:1 to:

  1. SOC (standard of care)
  2. SOC plus MAF Capsules (148 mg, 3 caps. TID for 14 days)
  3. SOC plus M Capsules (148 mg, 3 caps. TID for 14 days)

As compared to the control, both MAF groups showed a clear trend in decreasing mortality

  • No adverse events
  • Decrease in the mortality rate
  • Decrease in necessity and duration of supplemental oxygen
  • Decrease in time to recovery
  • Decrease in time until hospital discharge
  • Preventing of respiratory failure
  • Restoring the base-line decreased lymphocytes count
640_virus

US National Library of Medicine, NIH clinical trial

Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients (SaiseiCovUKR)
URL : https://clinicaltrials.gov/ct2/show/NCT04762628

800_aftereffect

Kazakhstan

The clinical trial using MAF capsules has started in Kazakhstan for the patients suffering with coronavirus aftereffects in February 2021.

Dr001

Ukraine

Update on the clinical trial using MAF for hospitalized COVID-19 patients in Ukraine.

1200x1200_M-Capsules_2bottles_1.jpg

Italy

The clinical trial using MAF capsules has started in Italy from November for hospitalised patients with COVID-19.

Cov19-bl.jpg

Ukraine

The clinical trial using MAF capsules has started in Ukraine from the end of October for hospitalised patients with COVID-19.

happy.jpg

Rationales of MAF as a therapeutic target for SARS-CoV-2

The fact that around 96% of patients recover from the infection

hands.jpg

Potential role of GcMAF

Potential role of GcMAF in suppressing the severity of COVID-19-induced immune responses: Lesson learned from HIV

640_virus

Saisei Pharma plans clinical study of oral MAF in COVID-19 patients

[Read more..]
Please check the below URL. [finanzen.ch] [advfn.com] [thechestnutpost.com] [benzinga.com]

3rd Generation GcMAF was developed by Saisei Pharma for which we hold patents. There are fake GcMAF products sold online in Australia by a company which is registered in Hong Kong. Please be aware that 3rd Generation GcMAF products are only produced by Saisei Pharma. Any other products from other companies are fake products.

media listing information

The decision is based on published preclinical evidence, preliminary reports from independent studies and is supported by data of the safety and efficacy of oral MAF in conditions that require the involvement of macrophages as the front line defense in innate immunity.  [Read more..]

Our Press Release featured on the following sites:
[finanzen.ch] [advfn.com] [benzinga.com]

Saisei Pharma

plans clinical study of oral MAF in COVID-19 patients

M Lollies & M Powder [50% OFF] while stocks last

M Lollies & M Powder [50%OFF Short Dated Sale] while stocks last

MAF Capsules and M-Lollies are approved as food supplements
MAF CAPSULES
Image is not available
初乳MAF
GALT, or gut associated lymphoid tissue, is said to be the biggest macrophage pool in the body.
And it is known that plenty of macrophages exist in the Peyer's patches. MAF CAPSULES aims to activate these macrophages directly.
GALT, or gut associated lymphoid tissue, is said to be the biggest macrophage pool in the body.
And it is known that plenty of macrophages exist in the Peyer's patches. MAF CAPSULES aims to activate these macrophages directly.
GALT, or gut associated lymphoid tissue, is said to be the biggest macrophage pool in the body.
And it is known that plenty of macrophages exist in the Peyer's patches. MAF CAPSULES aims to activate these macrophages directly.
Enteric coated capsule enables to reach to the gut
Enteric coated capsule enables to reach to the gut
Enteric coated capsule enables to reach to the gut
capsule
Image is not available
capsule
MAF CAPSULES
MAF CAPSULES
MAF CAPSULES
MAF CAPSULES [TRIPLE]
Image is not available
初乳MAF
GALT, or gut associated lymphoid tissue, is said to be the biggest macrophage pool in the body.
And it is known that plenty of macrophages exist in the Peyer's patches. MAF CAPSULES aims to activate these macrophages directly.
GALT, or gut associated lymphoid tissue, is said to be the biggest macrophage pool in the body.
And it is known that plenty of macrophages exist in the Peyer's patches. MAF CAPSULES aims to activate these macrophages directly.
GALT, or gut associated lymphoid tissue, is said to be the biggest macrophage pool in the body.
And it is known that plenty of macrophages exist in the Peyer's patches. MAF CAPSULES aims to activate these macrophages directly.
Enteric coated capsule enables to reach to the gut
Enteric coated capsule enables to reach to the gut
Enteric coated capsule enables to reach to the gut
capsule
Image is not available
capsule
MAF CAPSULES
[ TRIPLE ]
MAF CAPSULES
MAF CAPSULES
M-Lollies
Image is not available
M-Lollies
Image is not available
Image is not available
Image is not available
M-Lollies
M-Lollies
Tonsils, a lymphoid tissue exists around Pharynx.
This is called Waldeyer's ring which protects body by bacteria and viruses coming from nose and mouth.
M-Lollies is a hard candy with mild milky taste.
While enjoying this delicious lolly, the immune activating factor will be absorbed by lymphoid tissue. This is also beneficial for those who
cannot swallow capsules.
Hard Candy type will be absorbed in the mouth effectively
M-Lollies
Tonsils, a lymphoid tissue exists around Pharynx.
This is called Waldeyer's ring which protects body by bacteria and viruses coming from nose and mouth.
M-Lollies is a hard candy with mild milky taste.
While enjoying this delicious lolly, the immune activating factor will be absorbed by lymphoid tissue. This is also beneficial for those who
cannot swallow capsules.
Tonsils, a lymphoid tissue exists around Pharynx.
This is called Waldeyer's ring which protects body by bacteria and viruses coming from nose and mouth. M-Lollies is a hard candy with mild milky taste. While enjoying this delicious lolly, the immune activating factor will be absorbed by lymphoid tissue. This is also beneficial for those who cannot swallow capsules.
Hard Candy type will be absorbed in the mouth effectively
M-Powder
Image is not available
M-Powder
Image is not available
M-Powder
M-Powder
M-Powder will be absorbed in the tissues of the mouth and esophagus by taking M-powder without mixing with water straight into mouth, then slowly dissolve and swallow. This will activate the immune cells.
M-Powder is recommended for those who cannot swallow capsules, and/or who would like to have it without water on the go.
Comes in form that melts quickly in
the mouth and is absorbed quickly and efficiently.
Convenient ON-THE-GO packaging,
individual stick type.
Consume without water,
put straight to the mouth and slowly
let it melt.
M-Lollies
M-Powder
M-powder will be absorbed in the tissues of the mouth and esophagus by taking M-powder without mixing with water straight into mouth, then slowly dissolve and swallow. This will activate the immune cells. M-Powder is recommended for those who cannot swallow capsules, and/or who would like to have it without water on the go.
Comes in form that melts quickly in the mouth and is absorbed quickly and efficiently.
previous arrow
next arrow
MAF CAPSULES
MAF CAPSULES [TRIPLE]
M-Lollies
M-Powder
previous arrow
next arrow
Shadow

- Macrophage Activating Factor Vitamin D-

MAF Series

We have created 4 types of MAF products to cover many areas such as mouth, gut and skin

*Macrophage Activating Factor Vitamin D – MAF series are Saisei Mirai Clinic’s very own products which we researched, developed and produce.

MAF CAPSULES

MAF CAPSULES [TRIPLE ]

M-Lollies

M-Powder

About Us

About Saisei Pharma

Saisei Pharma is a bio venture company established at Tokushima university in 2014.

We develop, research and manufacture immune activating food products “MAF Series (Capsule, Spray, Candy, Powder)”, ultrasonic sensitizers and electric field therapy (TTF, ECCT) etc.

Our online store offers our Immune activating food products “MAF series” to domestic and overseas customers.

We are now located in Osaka, and our products are produced in a GMP certified factory in Moriguchi, Osaka.

As a Saisei Mira Group, we cooperate with each clinic and will continue our research and development aiming to treat many diseases such as acute infection, chronic infection, cancer, autism, chronic fatigue syndrome, multiple sclerosis, rheumatoid arthritis, Alzheimer’s disease, dementia and so on.

MAF Series
maf_4
Free from

Wheat, soy, egg, rice, gluten, starch, sugar (excluding M-Lollies), hormones, antibiotics, preservatives, artificial sweeteners, artificial colours.

maf_3
Easy to take

1 Colostrum MAF capsule contains 1 mg of Saisei Mirai’s unique MAF (Equivalent to 100 ng of Macrophage Activating Factor) Colostrum-MAF™.

maf_2
Produced in GMP Certified factory in Japan

MAF Series products are produced in our Saisei Mirai GMP Certified factory (Certification No. 26518) in Moriguchi, Osaka, certified by the Ministry of Health, Labor and Welfare of Japan.

250_powder
Very unique MAF

We have developed our very own unique MAF (macrophage activating factor) using our patented method. MAF helps boost the immune system by activating macrophages without any side effects.

Saisei Pharma MAF Series

Saisei Mirai Group

Saisei Mirai Group

We have partnered with 5 domestic clinics in Japan which are based on Saisei Mirai Medical Corporation, bio-venture companies, pharmacies, and universities and medical institutions in Japan and overseas, and have started providing advanced medical care worldwide.

Wholesale Distributor

Wholesale Distributor

Introducing overseas distributors that sell our products.
Momadeus.com

Sweden
shipping within EU countries

MACOTİZM

SPORTİF TESİSLER İŞLETMECİLİĞİ VE DANIŞMANLIK TİC LTD ŞTİ - Turkey

MACMAF

MacMAF is a company owned by macotism

MedInc

Kazakhstan
Uzbekistan, Kyrgyzstan

Products

Saisei Pharma products

1

Macrophage activating factor Vitamin D
MAF series

The MAF Series will help boost the immune system by activating immune cells without any side effects.
This anti-aging support food is for those who would like to stay young and healthy. The MAF Series is made with natural ingredients and produced in our GMP Certified factory (Certification No. 26518) in Osaka.

2

Ultrasonic Sensitizers

We have developed our very own Ultrasonic Sensitizers for Sonodynamic Therapy (SDT) which are used at Saisei Mirai Clinics. The sensitizer is taken up only by cancer cells, and the ultrasound energy beam activates the sensitizer to destroy only the cancer cells. Based on our own research, we have developed the latest non-toxic sensitizers.

3

Electric Field Therapy

Saisei Mirai Clinics offers Electric Field Therapy (TTF, ECCT). We have Blanket, Vest and Cap type applicators. The size and electric field is customized to suit each patient’s disease and lesion. Treatment is conducted at home and the electric field is adjusted and results are checked with a CT and/or MRI scan once every 1 to 3 months.

Contact us

Contact us